Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age2-80
SponsorTianjin Medical University

About this trial

Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis

Eligibility criteria

Qualifiers

Patients voluntarily participate in studies and sign informed consent forms

Ages 2-80 years (with cut-off values) male and female

One of the following is true (1)In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation/cord blood transplantation, the white blood cell count is less than 4× 10^9/L, and the platelet count ranges are 25× 10^9/L≤ PLT<100×10^9/L,Intravitreal injection carries a greater risk of infection and bleeding, and is unable to administer systemic medication due to the bone marrow suppression of antiviral drugs, or systemic medication for severe CMV retinitis cannot be well controlled; (2)In patients with CMVR with AIDS, the CD4+ T cell count is less than 100/μl, there is a great risk of infection with intravitreal injection, and the systemic medication of severe CMV retinitis cannot be well controlled.

Disqualifiers

Eye condition

The presence of refractive interstitial opacification affects fundus observation;

Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline;

Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal lesions, congenital macular degeneration, etc.

Trial design

Treatments tested in this trial

  • 2% Ganciclovir Eye Drops

Treatment groups

15 Participants
are divided into 1 treatment group

Sponsors and collaborators